top of page
< Back

Certolizumab

賽妥珠單抗

Mechanism of action:

Certolizumab 是一種抗腫瘤壞死因子 α（anti-TNF-α）單株抗體片段。TNF-α 是一種由巨噬細胞、T 細胞等免疫細胞分泌的促發炎細胞激素，是自體免疫疾病中主要引起發炎反應的因子之一。Certolizumab 為重組 Fab' 片段，並經聚乙二醇化（PEGylation）以延長體內半衰期，且不含 Fc 片段，能專一性地結合 TNF-α，阻止其與 p55（TNFR1）、p75（TNFR2）受體結合，從而抑制下游發炎訊息途徑。

​Reference(s):

1. Corbett M et al. (2017). Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation. Health Technol Assess. 


2. Bermejo I et al. (2017). Certolizumab pegol for treating rheumatoid arthritis following inadequate response to a TNF-alpha inhibitor: An evidence review group perspective of a NICE single technology appraisal. Pharmacoeconomics.

bottom of page